The mission of the Case CCC is to develop and support a highly collaborative and translational clinical trials program, which is fully integrated and bridges the Case CCC scientific partner institutions at UHC and CCF. The goal is to provide access for cancer patients residing in northeast Ohio to state-of-the-art clinical trials, to develop new anticancer therapies, and to contribute to the clinical science of advancing therapeutics for the cancer patient. The Clinical Trials Shared Resource, also referred to as the Clinical Trials Unit (CTU) core facility, is responsible for the registration of patients and/or participants and data acquisition for all cancer protocols, including externally peer reviewed, institutional, pharmaceutical sponsored, and cooperative group clinical trials at UHC and CCF. The CTU is part of the overall support for clinical trials research and is coordinated with the PRMS, the DSMP, and is aligned with the priorities of clinical research as outlined by program and senior leaders. The coordination functions of the CTU have been developed and redeployed to reflect the coordination of activities supporting clinical trials research at the partner institutions. These processes were approved after review by the Case CCC EAB. Under the partnership arrangement, two prominent and clinically active institutions, UHC and CCF, combine efforts in clinical trials cancer research. The responsibility of the CTU is to coordinate these activities, providing oversight for research staff training, quality assurance and audit review, developing policy and procedures for clinical trials activation, accrual and management, and having a procedure for management of disagreements and operational details. Since the CTU serves as the clinical trials research coordinating center, which is expected to expand to include oversight to other hospitals that are affiliated with Case (Metro Health and the Cleveland VA), or owned by the hospital systems of UHC or CCF (a total of 7 other affiliated institutions), the Case CCC needs to have strong centralized authority. To this end, the CTU is organized to include centralized functions within the Case CCC and distributed responsibilities that reside within the partnership hospitals, currently the Ireland Cancer Center of UHC and the Taussig Cancer Center of CCF. In 2005, a total of 3,249 patients were enrolled onto Case CCC clinical trials, including 877 therapeutic (31% of whom are registered to investigatorinitiated trials) and 2,366 non-therapeutic studies. PERFORMANCE SITE(S) (organization, city, state) University Hospitals of Clevel

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA043703-20
Application #
7799314
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-04-01
Budget End
2010-03-31
Support Year
20
Fiscal Year
2009
Total Cost
$704,861
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Anderson, Christian E; Wang, Charlie Y; Gu, Yuning et al. (2018) Regularly incremented phase encoding - MR fingerprinting (RIPE-MRF) for enhanced motion artifact suppression in preclinical cartesian MR fingerprinting. Magn Reson Med 79:2176-2182
Burger, Denis R; Parker, Yvonne; Guinta, Kathryn et al. (2018) PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Rynull Mice. Biol Blood Marrow Transplant 24:260-266
Shi, Xiaojun; Wang, Bingcheng (2018) Caught in the ""Akt"": Cross-talk between EphA2 and EGFR through the Akt-PIKfyve axis maintains cellular sensitivity to EGF. Sci Signal 11:
Tartakoff, Alan Michael; Dulce, David; Landis, Elizabeth (2018) Delayed Encounter of Parental Genomes Can Lead to Aneuploidy in Saccharomyces cerevisiae. Genetics 208:139-151
Gromovsky, Anthony D; Schugar, Rebecca C; Brown, Amanda L et al. (2018) ?-5 Fatty Acid Desaturase FADS1 Impacts Metabolic Disease by Balancing Proinflammatory and Proresolving Lipid Mediators. Arterioscler Thromb Vasc Biol 38:218-231
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Hubler, Zita; Allimuthu, Dharmaraja; Bederman, Ilya et al. (2018) Accumulation of 8,9-unsaturated sterols drives oligodendrocyte formation and remyelination. Nature 560:372-376
Asthana, Abhishek; Ramakrishnan, Parameswaran; Vicioso, Yorleny et al. (2018) Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death. Mol Cancer Ther 17:2226-2237
Belur Nagaraj, Anil; Kovalenko, Olga; Avelar, Rita et al. (2018) Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer. Clin Cancer Res 24:4588-4601
Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643

Showing the most recent 10 out of 1227 publications